Market Cap 4.01B
Revenue (ttm) 62.38M
Net Income (ttm) -101.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.86%
Debt to Equity Ratio 0.00
Volume 2,279,200
Avg Vol 2,339,400
Day's Range N/A - N/A
Shares Out 168.61M
Stochastic %K 55%
Beta 1.12
Analysts Strong Sell
Price Target $43.50

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 320 4900
Address:
201 Brookline Avenue, Suite 901, Boston, United States
danielmaia12
danielmaia12 Sep. 9 at 8:21 PM
$TNGX 92% response rate in pancreatic cancer combo!.!
0 · Reply
TA8688
TA8688 Sep. 9 at 2:51 PM
$TNGX Squeeze time
0 · Reply
mohamettarik
mohamettarik Sep. 9 at 2:04 PM
$TNGX a stock moves on zero news... I know from beginning it is one of biggest manipulative stocks in market. I don't hold any for your info before you attack.. Good luck.. Wake up on a crisis
0 · Reply
CrispDry
CrispDry Sep. 9 at 1:53 PM
$TNGX moving on something
0 · Reply
Radical777
Radical777 Sep. 9 at 1:47 PM
$TNGX Anyone know where the Cantor live feed might be?
0 · Reply
Jhoooon
Jhoooon Sep. 2 at 3:30 PM
$BMEA Biomea, at ~$1.70, is an extreme deep-value setup. People laugh at a $30+ PT scenario on positive diabetes/obesity data, yet they forgot $TNGX went from ~$1.03 in May 2025 to over 32 in May 2026 (now ~24)—a near 32x multi-bagger in 12 months. In small-cap biotech, paradigm shifts trigger violent re-ratings once clinical efficacy is validated. If Biomea’s covalent menin inhibitor platform delivers solid glycemic control/beta-cell rescue and metabolic data without safety hurdles, a multi-billion TAM justifies a return to $30$40+ within a year or so. Asymmetric risk/reward. Data is key. 🚀
0 · Reply
Redbet69
Redbet69 Sep. 2 at 1:47 PM
$TNGX Still waiting
0 · Reply
Jhoooon
Jhoooon Aug. 30 at 6:02 PM
$BMEA $BMEA at ~$1.70 is an extreme deep-value setup. People laugh at a $30+ PT scenario on positive diabetes/obesity data, yet they forgot $TNGX went from ~$1.03 in May 2025 to over 32 in May 2026 (now ~24)—a near 32x multi-bagger in 12 months. In small-cap biotech, paradigm shifts trigger violent re-ratings once clinical efficacy is validated. If Biomea’s covalent menin inhibitor platform delivers solid glycemic control/beta-cell rescue and metabolic data without safety hurdles, a multi-billion TAM justifies a return to $30$40+ within a year or so. Asymmetric risk/reward. Data is key. 🚀📊
2 · Reply
biolover
biolover Aug. 28 at 10:59 PM
$VKTX That how I feel now vs bio hedge funds. Happened also a year ago when they were selling $TNGX at $1
2 · Reply
PrivateTrading
PrivateTrading Aug. 26 at 7:23 PM
$TNGX At a market cap of roughly $4B with $1B in cash that covers expenses into 2028 and the association with Revolution Medicines newly approved RASONQUE (daraxonrasib), I think that TNGX would be a target for a major pharmaceutical.
0 · Reply
Latest News on TNGX
Tango Therapeutics reports Q2 EPS (37c), consensus (32c)

2026-08-11T11:15:11.000Z - 4 weeks ago

Tango Therapeutics reports Q2 EPS (37c), consensus (32c)


Tango Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Tango Therapeutics Quarterly report: Q2 2026


Tango Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Tango Therapeutics Earnings release: Q2 2026


Tango Therapeutics executive chairman Weber to step down

2026-08-06T22:55:27.000Z - 5 weeks ago

Tango Therapeutics executive chairman Weber to step down


Tango Therapeutics Announces Executive Chair Transition

Aug 6, 2026, 6:24 PM EDT - 5 weeks ago

Tango Therapeutics Announces Executive Chair Transition


Tango Therapeutics initiated with an Overweight at JPMorgan

2026-07-15T09:10:36.000Z - 2 months ago

Tango Therapeutics initiated with an Overweight at JPMorgan


Tango Therapeutics upgraded to Buy from Hold at Jefferies

2026-06-25T20:10:32.000Z - 2 months ago

Tango Therapeutics upgraded to Buy from Hold at Jefferies


Tango Therapeutics Appoints Robert Azelby to Board of Directors

Jun 22, 2026, 4:05 PM EDT - 2 months ago

Tango Therapeutics Appoints Robert Azelby to Board of Directors


Tango Therapeutics 18.2M share Secondary priced at $30.00

2026-06-10T10:08:24.000Z - 3 months ago

Tango Therapeutics 18.2M share Secondary priced at $30.00


Tango Therapeutics announces $500M common stock offering

2026-06-08T20:05:49.000Z - 3 months ago

Tango Therapeutics announces $500M common stock offering


Tango Therapeutics Transcript: Study result

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Tango Therapeutics Transcript: Study result


Tango Therapeutics Press release: Study result

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Tango Therapeutics Press release: Study result


Tango Therapeutics Slides: Study result

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Tango Therapeutics Slides: Study result


Tango Therapeutics Slides: Investor presentation

Jun 8, 2026, 7:00 AM EDT - 3 months ago

Tango Therapeutics Slides: Investor presentation


Tango Therapeutics Transcript: AGM 2026

Jun 4, 2026, 9:00 AM EDT - 3 months ago

Tango Therapeutics Transcript: AGM 2026


Tango Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Tango Therapeutics Quarterly report: Q1 2026


Tango Therapeutics Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Tango Therapeutics Earnings release: Q1 2026


Tango Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Tango Therapeutics Proxy statement: Proxy filing


Tango Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Tango Therapeutics Proxy statement: Proxy filing


Tango Therapeutics Annual report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 6 months ago

Tango Therapeutics Annual report: Q4 2025


Tango Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 9:00 AM EST - 6 months ago

Tango Therapeutics Earnings release: Q4 2025


Tango Therapeutics Slides: Corporate presentation

Mar 5, 2026, 6:00 AM EST - 6 months ago

Tango Therapeutics Slides: Corporate presentation


Tango Therapeutics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 8 months ago

Tango Therapeutics Slides: Corporate presentation


Tango Therapeutics Appoints Sung Lee to Board of Directors

Jan 5, 2026, 7:00 AM EST - 8 months ago

Tango Therapeutics Appoints Sung Lee to Board of Directors


Tango Therapeutics Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 9 months ago

Tango Therapeutics Registration statement: Registration Filing


Tango Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 9:00 AM EST - 10 months ago

Tango Therapeutics Earnings release: Q3 2025


Tango Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 9:00 AM EST - 10 months ago

Tango Therapeutics Quarterly report: Q3 2025


Tango Therapeutics Transcript: Study Update

Oct 23, 2025, 8:30 AM EDT - 10 months ago

Tango Therapeutics Transcript: Study Update


Tango Therapeutics Press release: Study Update

Oct 23, 2025, 8:30 AM EDT - 10 months ago

Tango Therapeutics Press release: Study Update


Tango Therapeutics Slides: Study Update

Oct 23, 2025, 8:30 AM EDT - 10 months ago

Tango Therapeutics Slides: Study Update


Tango Therapeutics Announces $225 Million Financing

Oct 23, 2025, 7:20 AM EDT - 10 months ago

Tango Therapeutics Announces $225 Million Financing


Tango Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 9:30 AM EDT - 1 year ago

Tango Therapeutics Quarterly report: Q2 2025


Tango Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 9:30 AM EDT - 1 year ago

Tango Therapeutics Earnings release: Q2 2025


Tango Therapeutics Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Tango Therapeutics Quarterly report: Q1 2025


Tango Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Tango Therapeutics Earnings release: Q1 2025


Tango Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics Earnings release: Q4 2024


Tango Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics Annual report: Q4 2024


Tango Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Quarterly report: Q3 2024


Tango Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Earnings release: Q3 2024


Tango Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Quarterly report: Q2 2024


Tango Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Earnings release: Q2 2024


Tango Therapeutics Slides: Corporate Presentation

Jun 11, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Slides: Corporate Presentation


Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:19 AM EDT - 2 years ago

Tango Therapeutics to stop development of cancer therapy


Tango Therapeutics Announces Discontinuation of TNG348 Program

May 23, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces Discontinuation of TNG348 Program


Tango Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Quarterly report: Q1 2024


Tango Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Earnings release: Q1 2024


Tango Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Earnings release: Q4 2023

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Earnings release: Q4 2023


Tango Therapeutics Annual report: Q4 2023

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Annual report: Q4 2023


Tango Therapeutics Slides: Corporate Presentation

Nov 13, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Slides: Corporate Presentation


Tango Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 7:15 AM EST - 2 years ago

Tango Therapeutics Quarterly report: Q3 2023


Tango Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 7:15 AM EST - 2 years ago

Tango Therapeutics Earnings release: Q3 2023


Tango Therapeutics Announces Updates to Its Board of Directors

Aug 29, 2023, 5:08 PM EDT - 3 years ago

Tango Therapeutics Announces Updates to Its Board of Directors


Tango Therapeutics Quarterly report: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Tango Therapeutics Quarterly report: Q2 2023


Tango Therapeutics Earnings release: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Tango Therapeutics Earnings release: Q2 2023


danielmaia12
danielmaia12 Sep. 9 at 8:21 PM
$TNGX 92% response rate in pancreatic cancer combo!.!
0 · Reply
TA8688
TA8688 Sep. 9 at 2:51 PM
$TNGX Squeeze time
0 · Reply
mohamettarik
mohamettarik Sep. 9 at 2:04 PM
$TNGX a stock moves on zero news... I know from beginning it is one of biggest manipulative stocks in market. I don't hold any for your info before you attack.. Good luck.. Wake up on a crisis
0 · Reply
CrispDry
CrispDry Sep. 9 at 1:53 PM
$TNGX moving on something
0 · Reply
Radical777
Radical777 Sep. 9 at 1:47 PM
$TNGX Anyone know where the Cantor live feed might be?
0 · Reply
Jhoooon
Jhoooon Sep. 2 at 3:30 PM
$BMEA Biomea, at ~$1.70, is an extreme deep-value setup. People laugh at a $30+ PT scenario on positive diabetes/obesity data, yet they forgot $TNGX went from ~$1.03 in May 2025 to over 32 in May 2026 (now ~24)—a near 32x multi-bagger in 12 months. In small-cap biotech, paradigm shifts trigger violent re-ratings once clinical efficacy is validated. If Biomea’s covalent menin inhibitor platform delivers solid glycemic control/beta-cell rescue and metabolic data without safety hurdles, a multi-billion TAM justifies a return to $30$40+ within a year or so. Asymmetric risk/reward. Data is key. 🚀
0 · Reply
Redbet69
Redbet69 Sep. 2 at 1:47 PM
$TNGX Still waiting
0 · Reply
Jhoooon
Jhoooon Aug. 30 at 6:02 PM
$BMEA $BMEA at ~$1.70 is an extreme deep-value setup. People laugh at a $30+ PT scenario on positive diabetes/obesity data, yet they forgot $TNGX went from ~$1.03 in May 2025 to over 32 in May 2026 (now ~24)—a near 32x multi-bagger in 12 months. In small-cap biotech, paradigm shifts trigger violent re-ratings once clinical efficacy is validated. If Biomea’s covalent menin inhibitor platform delivers solid glycemic control/beta-cell rescue and metabolic data without safety hurdles, a multi-billion TAM justifies a return to $30$40+ within a year or so. Asymmetric risk/reward. Data is key. 🚀📊
2 · Reply
biolover
biolover Aug. 28 at 10:59 PM
$VKTX That how I feel now vs bio hedge funds. Happened also a year ago when they were selling $TNGX at $1
2 · Reply
PrivateTrading
PrivateTrading Aug. 26 at 7:23 PM
$TNGX At a market cap of roughly $4B with $1B in cash that covers expenses into 2028 and the association with Revolution Medicines newly approved RASONQUE (daraxonrasib), I think that TNGX would be a target for a major pharmaceutical.
0 · Reply
KetCopyPaste
KetCopyPaste Aug. 26 at 3:49 PM
$TNGX News?
1 · Reply
Redbet69
Redbet69 Aug. 26 at 1:50 PM
$TNGX waiting for big news
0 · Reply
Jhoooon
Jhoooon Aug. 25 at 7:21 AM
$BMEA $BMEA at $1.59, $2, $3, $5... Does it really matter? Considering the potential here, if the data is as good as we hope, this is easily a $30 to $50 stock, nothing less. As is often the case with hidden gems, nobody touches them while they're overlooked. But as soon as the big players start stepping in, everyone rushes in and the opportunity to get in cheap is gone. Reminds me of $TNGX last year at $1.03... In just 12 months, it surged to over $32. Yes, you read that right: a 32x in one year...
2 · Reply
JFais
JFais Aug. 17 at 8:27 PM
$TNGX (NP) KRAS/MTAP play down here at $25 interesting Calm before the storm for a potential buyout ($RVMD running up to $45B market cap, would be wise to put its highly valued shares to work)
0 · Reply
Quantumup
Quantumup Aug. 17 at 1:12 PM
Stifel reiterated $TNGX Buy-$40 and said -- Expectations for the vopimetostat+RAS(ON) inhibitor combination ESMO 2026 poster? Expect longer follow-up from the June disclosure, with some additional patients. $RVMD $IMRX ERAS BBOT Stifel added—Management cautioned against expecting too many newly enrolled patients to be reflected in ESMO efficacy data – time window is pretty narrow to enroll patients who would have the 14+ weeks of required follow-up to be efficacy evaluable by the ESMO data cut-off. Investors expect around a doubling of the efficacy evaluable vopi+darax patients in PDAC (DL1+DL2) in the ESMO poster. This plays well for the 92% ORR holding up reasonably well, newly evaluable patients would have to meaningfully underperform the original n = 12 to pull down the ORR. Management said enrolling more patients in the vopi+darax dose level 1 has been their priority.
0 · Reply
JFais
JFais Aug. 14 at 1:46 PM
$TNGX - price alert went off on dip below $25. Back on DD list
0 · Reply
ripster47
ripster47 Aug. 12 at 3:44 PM
$TNGX This Pancreatic Cancer Gem is giving another technical Setup "92% Response Rate in pancreatic Cancer and Runup into Phase 3 Data" We stopped out last time. For In Depth Analysis check @tenet_research Target remains 30/34+ on this triple bottom gap bounce @Pharmdca https://x.com/TenetCharts
0 · Reply
Quantumup
Quantumup Aug. 12 at 1:18 PM
Guggenheim⬆️ $TNGX to $35, keeps Buy/said: TNGX reported 2Q26 results and highlighted that they will finalize the design of a planned Phase 3 randomized controlled trial for vopimetostat (PRMT5i) + RAS inhibitors ( $RVMD) in 1L PDAC in 2H26. IMRX $ERAS BBOT Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2087528805401280908?s=20
0 · Reply
divyadutta
divyadutta Aug. 10 at 11:57 PM
$TNGX What's up with 2Q 2026 results? For 2Q 2025 Tango put out a press release on 22nd July 2025 announcing the 2Q 20025 results date of 5th August 2025. This year the only recent news is on 6th August of executive chair transition.
1 · Reply
focafoca99
focafoca99 Aug. 6 at 11:54 PM
$TNGX disclosed its executive chair will step down to pursue other opportunities.
2 · Reply
ProbablyWrongAgain
ProbablyWrongAgain Aug. 6 at 2:29 PM
1 · Reply
AnniyanS
AnniyanS Jul. 29 at 1:21 PM
$TNGX what a shit show this has been since I bought...wtf
1 · Reply